Dilated Cardiomyopathy in an Adult Renal Transplant Recipient: Recovery Upon Tacrolimus to Sirolimus Switch: A Case Report

Abstract

Cardiac toxicity of tacrolimus is rare, less known but can be serious.  Tacrolimus cardiotoxicity should be suspected in unexplained cardiomyopathy post kidney transplant.  Sirolimus can be an effective alternative to preserve or improve cardiac function.

Identification of Hub Diagnostic Biomarkers and Candidate Therapeutic Drugs in Heart Failure

“…TGF-β is an important factor regulating myocardial fibrosis, which gradually worsens during HF and alters cardiac function from the compensatory phase to the decompensated phase. 48 Kakhi et al 49 found that sirolimus, an mTOR inhibitor, reversed new HF after kidney transplantation in mammals. Gao et al 50 also showed that rapamycin (sirolimus) can reduce cardiomyocyte apoptosis and promote autophagy by regulating mTOR and ERS, thus preventing myocardial damage caused by chronic HF.…”

Hypertrophic cardiomyopathy secondary to tacrolimus therapy in a kidney transplant patient: A case report and focused review of the literature

“… 15 , 16 Although hypertrophic cardiomyopathy due to tacrolimus is the most frequent type of cardiomyopathy, few cases of dilated cardiomyopathy have also been described. 17 , 18 …”

“…Less frequently, asymptomatic cases have been reported in which a new heart murmur was identified during follow‐up 15,16 . Although hypertrophic cardiomyopathy due to tacrolimus is the most frequent type of cardiomyopathy, few cases of dilated cardiomyopathy have also been described 17,18 …”